MedTrace Logo

Stratagen Quantitative Prostate MRI Platform Pilot Study

NCT06985238 · Status: RECRUITING · Phase: NA · Type: INTERVENTIONAL · Enrollment: 75

Last updated 2026-03-06

No results posted yet for this study

Summary

The goal of this clinical trial is to assess the safety and feasibility of the Stratagen Quantitative Prostate MRI Platform when used in addition to the standard scans conducted during the existing prostate MRI sessions.

* What severe problems, if any, occur because of the use of the Stratagen Quantitative Prostate MRI Platform?
* Can the data collected be used to measure quantitative MRI parameters?

Participants will:

\- Receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.

Conditions

Interventions

DEVICE

MRI

Will receive up to 15 minutes of additional MRI scan time during the existing prostate MRI imaging session.

Sponsors & Collaborators

  • Stratagen Bio, Inc.

    lead INDUSTRY

Study Design

Allocation
NA
Purpose
DEVICE_FEASIBILITY
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
40 Years
Max Age
90 Years
Sex
MALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-09-24
Primary Completion
2026-03-31
Completion
2026-10-31
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06985238 on ClinicalTrials.gov